These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22239224)

  • 1. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer.
    Langley S; Ahmed HU; Al-Qaisieh B; Bostwick D; Dickinson L; Veiga FG; Grimm P; Machtens S; Guedea F; Emberton M
    BJU Int; 2012 Feb; 109 Suppl 1():7-16. PubMed ID: 22239224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetry Modeling for Focal Low-Dose-Rate Prostate Brachytherapy.
    Al-Qaisieh B; Mason J; Bownes P; Henry A; Dickinson L; Ahmed HU; Emberton M; Langley S
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):787-93. PubMed ID: 25936808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversies in prostate cancer radiotherapy: consensus development.
    Lukka H; Warde P; Pickles T; Morton G; Brundage M; Souhami L;
    Can J Urol; 2001 Aug; 8(4):1314-22. PubMed ID: 11564274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI targeted single fraction HDR Brachytherapy for localized Prostate Carcinoma: a feasibility study of focal radiation therapy (ProFocAL).
    Fischbach F; Hass P; Schindele D; Genseke P; Geisendorf L; Stehning C; Schostak M; Brunner T; Pech M; Fischbach K
    Eur Radiol; 2020 Apr; 30(4):2072-2081. PubMed ID: 31828412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Delphi consensus study on salvage brachytherapy for prostate cancer relapse after radiotherapy, a Uro-GEC study.
    Kaljouw E; Pieters BR; Kovács G; Hoskin PJ
    Radiother Oncol; 2016 Jan; 118(1):122-30. PubMed ID: 26549865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage prostate brachytherapy in radiorecurrent prostate cancer: An international Delphi consensus study.
    Corkum MT; Buyyounouski MK; Chang AJ; Chung HT; Chung P; Cox BW; Crook JM; Davis BJ; Frank SJ; Henriquez I; Horwitz EM; Hoskin P; Hsu IC; Keyes M; King MT; Kollmeier MA; Krauss DJ; Kukielka AM; Morton G; Orio PF; Pieters BR; Potters L; Rossi PJ; Showalter TN; Solanki AA; Song D; Vanneste B; Vigneault E; Wojcieszek PA; Zelefsky MJ; Kamrava M
    Radiother Oncol; 2023 Jul; 184():109672. PubMed ID: 37059334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study.
    Peters M; van Son MJ; Moerland MA; Kerkmeijer LGW; Eppinga WSC; Meijer RP; Lagendijk JJW; Shah TT; Ahmed HU; van der Voort van Zijp JRN
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1045-1053. PubMed ID: 30926575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal radiotherapy as focal therapy of prostate cancer.
    Kovács G; Cosset JM; Carey B
    Curr Opin Urol; 2014 May; 24(3):231-5. PubMed ID: 24637315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy.
    Gomez-Veiga F; Mariño A; Alvarez L; Rodriguez I; Fernandez C; Pertega S; Candal A
    BJU Int; 2012 Feb; 109 Suppl 1():17-21. PubMed ID: 22239225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.
    Ahmed HU; Akin O; Coleman JA; Crane S; Emberton M; Goldenberg L; Hricak H; Kattan MW; Kurhanewicz J; Moore CM; Parker C; Polascik TJ; Scardino P; van As N; Villers A;
    BJU Int; 2012 Jun; 109(11):1636-47. PubMed ID: 22077593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal brachytherapy for selected low-risk prostate cancers: a pilot study.
    Cosset JM; Cathelineau X; Wakil G; Pierrat N; Quenzer O; Prapotnich D; Barret E; Rozet F; Galiano M; Vallancien G
    Brachytherapy; 2013; 12(4):331-7. PubMed ID: 23601349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemi-gland focal low dose rate prostate brachytherapy: An analysis of dosimetric outcomes.
    Laing R; Franklin A; Uribe J; Horton A; Uribe-Lewis S; Langley S
    Radiother Oncol; 2016 Nov; 121(2):310-315. PubMed ID: 27814981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting.
    Donaldson IA; Alonzi R; Barratt D; Barret E; Berge V; Bott S; Bottomley D; Eggener S; Ehdaie B; Emberton M; Hindley R; Leslie T; Miners A; McCartan N; Moore CM; Pinto P; Polascik TJ; Simmons L; van der Meulen J; Villers A; Willis S; Ahmed HU
    Eur Urol; 2015 Apr; 67(4):771-7. PubMed ID: 25281389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
    Mbeutcha A; Chauveinc L; Bondiau PY; Chand ME; Durand M; Chevallier D; Amiel J; Kee DL; Hannoun-Lévi JM
    Radiat Oncol; 2017 Mar; 12(1):49. PubMed ID: 28274241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focal high-dose-rate brachytherapy for localized prostate cancer: toxicity and preliminary biochemical results.
    Prada PJ; Cardenal J; García Blanco A; Andreescu J; Ferri M; Anchuelo J; Diaz de Cerio I; Sierrasesumaga N; Vázquez A; Pacheco M; Ruiz Arrebola S
    Strahlenther Onkol; 2020 Mar; 196(3):222-228. PubMed ID: 31942652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018.
    van der Poel HG; van den Bergh RCN; Briers E; Cornford P; Govorov A; Henry AM; Lam TB; Mason MD; Rouvière O; De Santis M; Willemse PM; van Poppel H; Mottet N
    Eur Urol; 2018 Jul; 74(1):84-91. PubMed ID: 29373215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial.
    Murgic J; Morton G; Loblaw A; D'Alimonte L; Ravi A; Wronski M; Davidson M; Haider M; Commisso K; Zhang L; Chung HT
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):561-567. PubMed ID: 30244878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of focal high-dose-rate brachytherapy in the treatment of patients diagnosed with low or favourable: intermediate-risk prostate cancer-a protocol for a randomised controlled trial.
    Jonušas J; Patasius A; Trakymas M; Venius J; Janulionis E; Smailyte G; Kincius M
    BMJ Open; 2023 May; 13(5):e070020. PubMed ID: 37197816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.